Jpmorgan Chase & Co »

Regulus Therapeutics shares owned by Jpmorgan Chase & Co

Quarter-by-quarter ownership of Regulus Therapeutics (RGLS) shares owned by Jpmorgan Chase & Co from 13F filings

Historical chart of Jpmorgan Chase & Co investment in Regulus Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Regulus Therapeutics held by Jpmorgan Chase & Co consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Regulus Therapeutics by Jpmorgan Chase & Co

Quarter filed Position value Share count Share price at filing
2024-03-31 $57k 20k 2.88
2023-12-31 $37 29 1.28
2023-09-30 $28 20 1.40

More positions owned by Jpmorgan Chase & Co

Microsoft Corp Common (MSFT)
Nvidia Corporation Common (NVDA)
SPDR S&P 500 ETF Ser 1 S&P Common (SPY)
Amazon Common (AMZN)
Apple Common (AAPL)
Meta Platforms Common (META)
Eli Lilly & Co Common (LLY)
Alphabet Common (GOOG)
Mastercard Incorporated Common (MA)
Unitedhealth Group Common (UNH)
Ishares Core S&p 500 Etf Fund (IVV)
Vanguard index Fds S&P 500 ETF Common (VOO)
Abbvie Common (ABBV)
Exxon Mobil Corp Common (XOM)
Alphabet Common (GOOGL)

View all positions for Jpmorgan Chase & Co

Top funds holding Regulus Therapeutics

RA Capital Management
Vivo Capital
Federated Investors
Adage Capital Partners GP
FMR
Millennium Management
Soleus Capital Management
CVI Holdings
DAFNA Capital Management
Alyeska Investment Group
Vanguard Group
Monashee Investment Management
Hudson Bay Capital Management
Polar Securities
Exome Asset Management

View all funds holding Regulus Therapeutics